Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Sun Pharmaceutical Industries Ltd.
  6. Summary
    SUNPHARMA   INE044A01036

SUN PHARMACEUTICAL INDUSTRIES LTD.

(SUNPHARMA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
767.3(c) 751.05(c) 753.6(c) 745.35(c) 766.25(c) Last
5 432 649 4 664 270 5 505 266 3 687 799 4 896 650 Volume
-1.99% -2.12% +0.34% -1.09% +2.80% Change
More quotes
Estimated financial data (e)
Sales 2022 384 B 5 121 M 5 121 M
Net income 2022 70 539 M 942 M 942 M
Net cash position 2022 95 702 M 1 278 M 1 278 M
P/E ratio 2022 25,9x
Yield 2022 0,65%
Sales 2023 421 B 5 623 M 5 623 M
Net income 2023 82 963 M 1 107 M 1 107 M
Net cash position 2023 152 B 2 025 M 2 025 M
P/E ratio 2023 22,4x
Yield 2023 0,74%
Capitalization 1 838 B 24 543 M 24 541 M
EV / Sales 2022 4,54x
EV / Sales 2023 4,00x
Nbr of Employees 37 000
Free-Float 80,9%
More Financials
Company
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as... 
Read more
Sector
Pharmaceuticals
Calendar
02/15Earnings Release
More about the company
Ratings of Sun Pharmaceutical Industries Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SUN PHARMACEUTICAL INDUSTRIES LTD.
11/29Indian Benchmarks Open the Week in Green; Kotak Mahindra Bank Jumps 3%
MT
11/23ECS Botanics Subsidiary, Sun Pharma Enter Supply, Toll Processing Deal for Medicinal Ca..
MT
11/12Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the..
AQ
11/11Sun Pharmaceutical to Likely Launch COVID-19 Treatment Drug Molxvir in India
MT
11/11Sun Pharmaceutical Industries Limited to Introduce Molnupiravir, Licensed from MSD and ..
CI
11/04Nomura Adjusts Sun Pharmaceutical Industries' Price Target to 1,010 Indian Rupees From ..
MT
11/03Indian Indices Remains in Red Midweek; Larsen & Toubro Jumps 4%
MT
11/03Sun Pharmaceutical Posts Gains in Q2 Consolidated Net Profit
MT
11/03Cassiopea's Partner Launches Winlevi Acne Treatment In US
MT
11/02Sun Pharma Eyes Acquisitions
CI
11/02Indian Indices Close Lower on Tuesday; Tata Steel Tanks 4%
MT
11/02Sun Pharmaceutical Industries Limited Reports Earnings Results for the Second Quarter a..
CI
11/02Indian shares slip as Sun Pharma drags ahead of earnings
RE
11/01Sun Pharmaceutical Industries Launches Acne Cream in US
MT
10/31Sun Pharmaceutical Industries Limited Announces the Availability of WINLEVI (Clascotero..
CI
More news
News in other languages on SUN PHARMACEUTICAL INDUSTRIES LTD.
11/29Les indices indiens ouvrent la semaine dans le vert ; Kotak Mahindra Bank bondit de 3%.
11/23La filiale d'ECS Botanics et Sun Pharma concluent un accord d'approvisionnement et de t..
11/11Sun Pharmaceutical va probablement lancer le Molxvir, un médicament pour le traitement ..
11/03BOURSE ZURICH : l'optimisme l'emporte avant les décisions de la Fed
11/03Les indices indiens restent dans le rouge en milieu de semaine ; Larsen & Toubro bondit..
More news
Analyst Recommendations on SUN PHARMACEUTICAL INDUSTRIES LTD.
More recommendations
Analysis
Indian pharma firms go local seeking to end reliance on China
Chart SUN PHARMACEUTICAL INDUSTRIES LTD.
Duration : Period :
Sun Pharmaceutical Industries Ltd. Technical Analysis Chart | SUNPHARMA | INE044A01036 | MarketScreener
Technical analysis trends SUN PHARMACEUTICAL INDUSTRIES LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 32
Last Close Price 766,25 INR
Average target price 912,39 INR
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
Dilip Shantilal Shanghvi Managing Director & Executive Director
C. S. Muralidharan Chief Financial Officer
Israel Makov Non-Executive Chairman
Atanu Roy SVP & Chief Information Officer
Davinder Singh Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
SUN PHARMACEUTICAL INDUSTRIES LTD.25.83%23 895
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.0.70%19 866
OTSUKA HOLDINGS CO., LTD.-8.31%19 454
ZHEJIANG NHU COMPANY LTD.3.50%11 763
ONO PHARMACEUTICAL CO., LTD.-20.09%10 975
CIPLA LIMITED13.20%10 006